This site is intended for healthcare professionals
Liver cirrhosis

CME accredited AATD liver disease podcast series

CME credits: 1.5
Read time: 90 mins
Last updated: 3rd Apr 2023
Published:3rd Apr 2023

Take part in our interactive CME accredited podcast series to explore the role of Alpha anti-trypsin deficiency (AATD) in liver disease. 1.5 CME credits will be awarded for successful completion of the podcast series and knowledge assessment.

  • Learn about the role of AATD in liver pathology
  • Discover how different AATD genotypes influence the severity of disease
  • Review the gold-standard guidelines for screening and diagnosis
  • Find out the latest recommendations for management and treatment

Listen to our podcast series to learn all this and more.

CME accredited AATD liver disease podcast series

Earn 1.5 CME credits by listening to this interactive CME accredited podcast series intended for healthcare professionals involved in hepatology, gastroenterology and pulmonology.

Learn more about the role of AATD in liver disease here.


Course overview

AATD is a rare genetic condition that predisposes individuals to developing severe liver and lung disease. Early screening and diagnosis are essential for optimal disease management, however many clinicians are unaware of the condition to begin with.

Refresh your clinical knowledge of AATD with our panel of experts, Professor Strnad, Professor Teckman and Dr Miravitlles in this CME accredited podcast series reviewing screening, diagnosis, management, and treatment of AATD.

At the completion of the podcast series, you will have the opportunity to test your knowledge in our interactive assessment. Upon successful completion, 1.5 CME credits will be awarded.

Podcast Content outline Time
(90 mins total)
1 What is AATD and how does it impact the liver and the lung? 24 mins
2 AATD genotypes involved in liver disease 27 mins
3 Screening, diagnosis, and guideline recommendations for AATD management 19 mins
4 Treatment options for AATD-associated liver disease and current unmet needs 20 mins

Learning objectives

On completion of this module, participants will understand:

  • Aetiology, pathology and genetic basis of AATD
  • Gold-standard guideline recommendations for screening and diagnosis of AATD
  • Strategies for treatment and management of AATD liver disease
  • Unmet needs in people with AATD and the future of AATD clinical research

Target Audience

This activity has been designed to meet the educational needs of gastroenterologists, hepatologists, pulmonologists, genetic counsellors, GPs and specialist nurses.


USF Health and EPG Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health and EPG Health any financial relationship with an ineligible organisation. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant financial relationships are listed below.

Meet the experts

Professor Pavel Strnad.pngProfessor Pavel Strnad

Clinic for Gastroenterology at the University Hospital RWTH Aachen, Germany

Professor Pavel Strnad is a full professor and leading physician at the University Hospital Aachen, Germany. Professor Strnad is heading a European initiative for the study of alpha1-antitrypsin deficiency-associated liver disease and is helping develop new therapies for this rare disorder. His scientific interests include metabolic liver disease, liver cirrhosis and complications, keratins and iron metabolism. His clinical focus is on novel treatments, end-stage liver disease and liver transplantation. 


Professor Jeffrey Teckman.pngProfessor Jeffrey Teckman

Division of Pediatric Gastroenterology in the Department of Pediatrics, Saint Louis University School of Medicine, United States

Professor Jeffrey Teckman is Professor of Pediatrics and Biochemistry at Saint Louis University School of Medicine and Cardinal Glennon Children's Hospital, and was named as the Drs. James and Patricia Monteleone Endowed Chair in Pediatric Gastroenterology and Hepatology. He has studied liver injury and the model of alpha-1-antitrypsin deficiency for 30 years and has participated in clinical research studies in a variety of diseases including alpha-1, cystic fibrosis, hepatitis C, hepatitis B, and metabolic diseases. He holds several patents in liver disease and has been a leader in bringing new therapies of alpha-1 disease to clinical trials.

Dr Marc Miravitlles.pngDr Marc Miravitlles

Hospital Universitari Vall d’Hebron / Vall d’Hebron Research Institute, Barcelona, Spain 

Dr Marc Miravitlles is senior researcher and consultant at Vall d’Hebron University Hospital in Barcelona. He was Chair of the Respiratory Infections Group of the European Respiratory Society (ERS) and Guidelines Director of the ERS. He has acted as a consultant for the development of international guidelines of COPD, including the American Thoracic Society (ATS)/ERS guidelines on exacerbations of COPD and the ERS statement on management of respiratory disease in alpha-1 antitrypsin deficiency (AATD). He was the founder of the Spanish Registry for AATD in 1992 and is the co-chair of EARCO, the European Alpha-1 Antitrypsin Deficiency Research Collaboration (EARCO) Registry of the ERS since 2018.

Faculty Disclosures

Dr Marc Miravitlles - Consultancy fees from Atriva Therapeutics, CSL Behring, Inhibrx, Mereo Biopharma (relationship terminated), Spin Therapeutics (relationship terminated), ONO Pharma (relationship terminated), Takeda, Novo Nordisk and Grifols.Grants/research suport from Grifols. Speaker’s bureau fees from Kamada, Takeda, CSL Behring and Grifols.

Professor Pavel Strnad - Advisory board or panel fees from Albireo, Dicerna, Intellia, Takeda, Ono Pharmaceuticals, CSL Behring, Grifols Inc. Consultancy fees from Dicerna, Intellia, Takeda, Ono Pharmaceuticals and Sanofi.Grants/research support from CSL Behring, Grifols, Arrowhead Pharmaceuticals, Vertex Pharmaceuticals and Dicerna Pharmaceuticals.

Professor Jeffrey Teckman - Advisory board or panel fees from Takeda and BioMarin. Consultancy fees from Arrowhead, Dicerna, BioMarin, NovoNordisk, Beam Therapeutics, Camp4 Therapeutics, Centessa, Intellia, KorroBio, NeuBase, Takeda, UniQure and Vertex.Grants research support from Arrowhead, BioMarin, Camp4 Therapeutics, KorroBio, Takeda, UniQure and Vertex.

Content Reviewer

 Reviewer, Alicia Canalejo, MSN, APRN-C has no financial interests/relationships or affiliations in relation to this activity.


USF Health and EPG Health staff have no relevant financial interests/relationships or affiliations in relation to this activity.

Requirements for successful completion

In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.

If you have questions regarding credit please contact



This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and EPG Health. USF Health is accredited by the ACCME to provide continuing medical education for physicians.

USF Health designates this enduring activity for a maximum of 1.5 AMA PRA Category 1.5 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1.5 CreditsTM  into European CME credit (ECMEC) should contact the UEMS (

Advanced Practice Providers

Physician Assistants may claim a maximum of 1.5 Category 1.5 credits for completing this activity. NCCPA accepts AMA PRA Category 1.5 CreditsTM from organisations accredited by ACCME or a recognized state medical society.

The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1.5 CreditsTM by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.

This Activity Is Funded By:

An independent medical education grant from Takeda.

This activity is jointly provided by USF Health and EPG Health.

The information provided by this CE activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.


This content has been developed independently of the sponsor, Takeda, which has had no editorial input into the content. Medthority received educational funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.